FEED Stock Forecast: ENvue Medical, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 25 of 100 as at 1 Aug 2026 — in the lower half.
FEED stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores ENvue Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (98): Smaller than most of the companies we track.
Value (9): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own ENvue Medical, Inc. — and when they’d sell — is the membership.
FEED stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on FEED, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
FEED analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
ENvue Medical, Inc. (FEED) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.0×
- Price / sales
- 0.9×
- Price / book
- 0.0×
- EV / EBITDA
- −0.1×
Cheaper than 75% of US stocks
Cheaper than 72% of US stocks
Cheaper than 91% of US stocks
Cheaper than 62% of US stocks
- Revenue growth (YoY)
- −36.3%
- Earnings growth (YoY)
- −36.3%
- Gross margin
- −8.4%
- Operating margin
- −568.3%
- Net margin
- 6.0%
Higher than 7% of US stocks
Higher than 14% of US stocks
Higher than 4% of US stocks
Higher than 7% of US stocks
Higher than 62% of US stocks
- Return on equity
- −59.5%
- Return on assets
- −20.2%
- Dividend yield
- —
Higher than 19% of US stocks
Higher than 19% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
FEED vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. FEED appears on the weeks it earns a place.
Frequently asked questions about FEED stock
How does Ticker Nerd's model rank FEED?
As at 1 Aug 2026, ENvue Medical, Inc. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).
What is the FEED stock forecast for 2030?
No analyst covering ENvue Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FEED are extrapolating price history, which says nothing about the business.
How has FEED stock performed over the past year?
ENvue Medical, Inc. returned -95.8% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does ENvue Medical, Inc. do?
ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use.
About ENvue Medical, Inc.
ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers UroShield Ultra, which is designed to prevent bacterial colonization and biofilm formation in urinary catheters; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures. In addition, it provides PainShield MD, a single patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; PainShield Plus, a dual patch-based therapeutic ultrasound technology; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally. ENvue Medical, Inc. was formerly known as NanoVibronix, Inc. and changed its name to ENvue Medical, Inc. in December 2025. The company was incorporated in 2003 and is based in Tyler, Texas.
CEO Dr. Doron Robert Besser M.D. · 12 employees · United States · https://envuemed.com